Facebook
X
LinkedIn
ForwardEvolving Treatment Strategies for Acute Myeloid Leukemia
Treatment decisions for acute myeloid leukemia are complex and are based on a variety of factors, including functional/performance status and comorbid medical conditions, factors that influence one’s ability to tolerate intensive therapy, as well as specific disease biology. There is a continuing need to educate clinicians about factors that help guide these decisions, particularly as treatment strategies are evolving. In the frontline setting, with increasing use of lower-intensity therapy options, data is emerging that certain genetic abnormalities that confer poor outcomes with intensive chemotherapy are associated with improved survival in the setting of lower intensity therapy. In the relapsed/refractory setting, novel therapies such as menin inhibitors are improving outcomes for patients with certain molecular abnormalities.
Target Audience
This program is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician assistants, and other health care professionals who manage patients with hematologic malignancies.
Learning Objectives
Following this activity, participants should be able to:
- Identify biologic disease factors that may confer improved outcomes with lower intensity induction therapy compared to standard intensive induction therapy.
- Describe the role of oral menin inhibitors in the treatment of acute myeloid leukemia and management of potential toxicities.
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
Presenting Faculty
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Congress Planning Committee
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Gabriela S. Hobbs, MD
Bristol Myers Squibb: Scientific Advisor
Cogent Biosciences: Consulting Fee
GSK: Scientific Advisor
Incyte Corporation: Grant/Research Support; Scientific Advisor
Novartis Pharmaceuticals Corporation: Scientific Advisor
PharmaEssentia: Consulting Fee
Pfizer Inc.: Consulting Fee
Regeneron Pharmaceuticals, Inc.: Equity Interest/Stock Options
Sobi - Swedish Orphan Biovitrum AB: Scientific Advisor
Shaji K. Kumar, MD
AbbVie, Inc.: Grant/Research Support; Scientific Advisor
Amgen Inc.: Grant/Research Support; Scientific Advisor
BD Biosciences: Consulting Fee
BioLineRx Ltd.: Consulting Fee
Bristol Myers Squibb: Grant/Research Support; Scientific Advisor
CARsgen Therapeutics Holdings Limited: Grant/Research Support
GSK: Grant/Research Support; Scientific Advisor
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
Moderna, Inc.: Consulting Fee
Oricell Therapeutics: Grant/Research Support
Regeneron Pharmaceuticals, Inc.: Grant/Research Support; Scientific Advisor
Roche Laboratories, Inc.: Grant/Research Support; Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support; Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support; Scientific Advisor
James K. Mangan, MD, PhD
Astellas Pharma US, Inc.: Product/Speakers Bureau
Autolus Therapeutics: Consulting Fee
CTI BioPharma Corp.: Consulting Fee
Daiichi-Sankyo Co.: Consulting Fee
Jazz Pharmaceuticals Inc.: Consulting Fee
Kura Oncology, Inc.: Scientific Advisor
Shoreline Biosciences: Consulting Fee
Bernard L. Marini, PharmD, BCOP
Servier: Consulting Fee
MiKaela M. Olsen, DNP, APRN-CNS, AOCNS, FAAN
BD Biosciences: Consulting Fee; Honoraria
Andrew D. Zelenetz, MD, PhD (Congress Chair and Moderator)
AbbVie, Inc.: Consulting Fee
Amgen, Inc.: Consulting Fee
Arvinas, Inc.: Grant/Research Support; Consulting Fee; Scientific Advisor
AstraZeneca Pharmaceuticals LP: Consulting Fees
BeiGene, Ltd. (now BeOne Medicines): Grant/Research Support, Consulting Fees
Bristol Myers Squibb: Consulting Fees
Curio Science: Consulting Fees
DAVA Oncology: Consulting Fees
Eli Lilly and Company: Consulting Fees; Scientific Advisor
Genentech, Inc.: Grant/Research Support; Consulting Fees
Genmab US, Inc.: Consulting Fees
Gilead Sciences, Inc./Kite Pharma, Inc.: Consulting Fees
Ipsen Biopharmaceuticals, Inc.: Consulting Fees
MEI Pharma, Inc.: Grant/Research Support; Consulting Fees
Roche Laboratories, Inc.: Grant/Research Support; Consulting Fees
NCCN Staff Disclosures
None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour. This program offers 1.0 pharmacotherapeutic contact hour for nurses.
Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-25-130-H01-P
Physician Associates
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until November 30, 2026. PAs should only claim credit commensurate with the extent of their participation.
American Board of Internal Medicine Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Aggregated participant data will be shared with the commercial supporters of this activity.
American Board of Pathology Continuing Certification (CC)
This activity has been registered to offer credit in the American Board of Pathology’s (ABPath) Continuing Certification program. Participants may earn up to 1.0 Lifelong Learning (Part II) credit.
Aggregated participant data will be shared with the commercial supporters of this activity.
American Board of Medical Specialties Maintenance of Certification (MOC)
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, NCCN 2025 Hematologic Malignancies Congress has met the requirements as a Lifelong Learning CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:
ABMS Lifelong Learning CME Activity
Radiology
Available Credit
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 ANCC Pharmacology Contact Hours
- 1.00 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing